Melinta To Launch First Commercial Drug Baxdela Independently
Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.
You may also be interested in...
CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.
A transaction bringing newly public Melinta three anti-infective products and a related sales force from The Medicines Co. will enable the latter to downsize and focus on its Phase III PCSK9 inhibitor inclisiran.
In all-stock transaction, troubled Cempra will merge with privately held Melinta to create a fully integrated anti-infectives company.